

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 October 2021 (21.10.2021)



(10) International Publication Number
WO 2021/212023 A1

(51) International Patent Classification:

C07K 14/575 (2006.01) A61P 3/10 (2006.01)
A61K 38/22 (2006.01) A61K 9/00 (2006.01)
A61P 3/04 (2006.01) A61K 38/00 (2006.01)

(21) International Application Number:

PCT/US2021/027759

(22) International Filing Date:

16 April 2021 (16.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/011,649 17 April 2020 (17.04.2020) US
63/076,459 10 September 2020 (10.09.2020) US

(71) Applicant: **INTARCIA THERAPEUTICS, INC.**
[US/US]; One Marina Park Drive, Suite 1300, Boston,
Massachusetts 02210 (US).

(72) Inventors: **BLACKWELL, William**; c/o Intarcia Therapeutics, Inc., One Marina Park Drive, Suite 1300, Boston, Massachusetts 02210 (US). **SRIVASTAVA, Ved P.**; c/o Intarcia Therapeutics, Inc., One Marina Park Drive, Suite 1300, Boston, Massachusetts 02210 (US). **WAY, James**

M.; c/o Intarcia Therapeutics, Inc., One Marina Park Drive, Suite 1300, Boston, Massachusetts 02210 (US).


(74) Agent: **TRINQUE, Brian C.**; 28 State Street, Suite 700, Boston, Massachusetts 02109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: LONG ACTING PEPTIDE TYROSINE TYROSINE (PYY) ANALOGS AND METHODS OF USE

FIGURE 1



(57) Abstract: This invention relates to isolated polypeptides that are long acting analogs of human PYY. The disclosed PYY analog polypeptides have beneficial physicochemical properties relative to endogenous PYY and known synthetic PYY analog polypeptides, such as longer (*i.e.*, "long-acting") elimination half-lives ($t_{1/2}$), and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed PYY analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed PYY analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as type 2 diabetes, treating obesity, and providing weight loss, and in methods of treating nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*